Contrasting Biohaven (NYSE:BHVN) & Adhera Therapeutics (OTCMKTS:ATRX)

Biohaven (NYSE:BHVN) and Adhera Therapeutics (OTCMKTS:ATRX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Risk and Volatility

Biohaven has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Adhera Therapeutics has a beta of 12, meaning that its share price is 1,100% more volatile than the S&P 500.

Profitability

This table compares Biohaven and Adhera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Adhera Therapeutics	N/A	N/A	N/A

Earnings & Valuation

This table compares Biohaven and Adhera Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82 million	($4.64)	-3.32
Adhera Therapeutics	N/A	N/A	N/A	($0.84)	N/A

Biohaven is trading at a lower price-to-earnings ratio than Adhera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Biohaven and Adhera Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2	4	9	2	2.65
Adhera Therapeutics	0	0	0	0	0.00

Biohaven currently has a consensus price target of $18.94, suggesting a potential upside of 22.89%. Given Biohaven’s stronger consensus rating and higher possible upside, equities analysts plainly believe Biohaven is more favorable than Adhera Therapeutics.

Insider and Institutional Ownership

88.8% of Biohaven shares are held by institutional investors. 13.8% of Biohaven shares are held by company insiders. Comparatively, 28.2% of Adhera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

About Adhera Therapeutics

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.